TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03739866

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered subcutaneously in the abdomen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B/F/TAF
Description: 50/200/25 mg tablets administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B/F/TAF
Description: 50/200/25 mg tablets administered orally once daily
Study: NCT02819843

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TALIMOGENE LAHERPAREPVEC (TVEC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TALIMOGENE LAHERPAREPVEC (TVEC)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated Radiotherapy
Study: NCT02733380

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 10mg/m2 , IV on day 1-5 of each 14 day cycle until disease progression or unacceptable toxicity develops, up to 12 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: 100mg,Oral at night on each day until disease progression or unacceptable toxicity develops, up to 24 weeks
Study: NCT04055038

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platinum-Based Drug
Description: Reintroduction of platinum-based chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conventional chemotherapy
Description: Conventional chemotherapy
Study: NCT04859530

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: AVC test
Description: The AVC test will be performed during VIA by local midwives: 120 second videos focused on the cervix will be taken right after the application of acetic acid on the cervix. The recording smartphone will be fixed on a tripod situated 15cm away from the cervix.
Study: NCT03220022

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Given SC
Study: NCT03097848

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: RFA
Description: for eligible cases, radiofrequency ablation will be given only.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RFA
Description: for eligible cases, radiofrequency ablation will be given only.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: for eligible cases, combination treatment with RFA and Sorafenib will be given.That is sorafenib for 2 week,then radiofrequency ablation
Study: NCT03220022

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT04283214

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiopulmonary Resuscitation
Description: Cardiopulmonary Resuscitation based on 2015 American Heart Association guidelines with and without protective equipment on traditional and endomorphic manikins
Study: NCT03220022

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: Given SC

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV
Study: NCT04283214

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiopulmonary Resuscitation
Description: Cardiopulmonary Resuscitation based on 2015 American Heart Association guidelines with and without protective equipment on traditional and endomorphic manikins

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cardiopulmonary Resuscitation
Description: Cardiopulmonary Resuscitation based on 2015 American Heart Association guidelines with and without protective equipment on traditional and endomorphic manikins

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiopulmonary Resuscitation
Description: Cardiopulmonary Resuscitation based on 2015 American Heart Association guidelines with and without protective equipment on traditional and endomorphic manikins
Study: NCT00765037

Intervention type: DEVICE
Intervention: Encore Reverse Shoulder Prosthesis
Description: rotator cuff deficiency and glenohumeral arthritis
Study: NCT02315807

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial direct current stimulation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation
Study: NCT01258465

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pivotal Response Training
Description: Naturalistic behavioral protocol designed to teach vocal communication.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Picture Exchange Communication System
Description: Pictorially-based behavioral protocol designed to teach communication to nonverbal children via pictures icons.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Picture Exchange Communication System
Description: Pictorially-based behavioral protocol designed to teach communication to nonverbal children via pictures icons.
Study: NCT00920387

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 200 mcg LSD
Description: Administering 200 mcg LSD orally once at the start of each of two day-long psychotherapy session

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 20 mcg LSD
Description: Administer 20 mcg LSD orally once at the start of each of two day-long psychotherapy session

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Therapy
Description: Therapy provided by male and female co-therapists

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapy
Description: Therapy provided by male and female co-therapists
Study: NCT01278121

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Diet A
Description: 3 days, 6 meals a day
Study: NCT03220022

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV
Study: NCT01747863

Intervention type: OTHER
Intervention: Neurologic examination
Description: Neurologic examination includes: (1) neurologic examination using modify Sarnat score at \</= 6 hrs of age, 24 hrs and at discharge home, (2) aEEG at 6 ± 3 hrs of age, (3) Brain MRI before discharge home to 30 days of age.
Study: NCT01278121

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Diet B
Description: 10 days, 6 meals a day
Study: NCT03739866

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B/F/TAF
Description: 50/200/25 mg tablets administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B/F/TAF
Description: 50/200/25 mg tablets administered orally once daily
Study: NCT04282096

Intervention type: OTHER
Group type: OTHER
Intervention: native and non native casein
Description: selected participant will test the 3 treatments in a random order

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: native and non native casein
Description: selected participant will test the 3 treatments in a random order

Intervention type: OTHER
Group type: OTHER
Intervention: native and non native casein
Description: selected participant will test the 3 treatments in a random order
Study: NCT01900132

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EIM testing
Description: EIM device is placed on the muscle and a high frequency current is delivered to the skin.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nerve &amp; muscle ultrasonography
Description: Ultrasound waves to examine the muscles and nerves

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nerve conduction studies
Description: Small metal disk electrodes attached to wires onto skin to measure how fast nerves conduct electrical impulses and the strength of the connection between nerves and muscles.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electromyography (EMG)
Description: Thin needle placed into muscles to record electrical activity-adults only
Study: NCT02033057

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Muscular electrostimulation and percutaneus muscular biopsy.
Description: Muscular electrostimulation everyday and percutaneus muscular biopsy weekly.
Study: NCT01504815

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatinum
Description: i.v. 100 mg/m2 on days 1, 22 and 43 of radiotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatinum
Description: i.v. 100 mg/m2 on days 1, 22 and 43 of radiotherapy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Conventional radiotherapy
Description: conventional radiotherapy, 70Gy in 7 weeks

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Adaptive radiotherapy
Description: adaptive high dose radiotherapy up to 84 Gy max on 50% uptake GTV in 7 weeks
Study: NCT03426163

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality
Description: Application of knee MRI transformed virtual reality system
Study: NCT00168818

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dabigatran etexilate
Description: daily dose 150 mg once daily, half a dose on the day of surgery
Study: NCT03739866

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B/F/TAF
Description: 50/200/25 mg tablets administered orally once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: B/F/TAF
Description: 50/200/25 mg tablets administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B/F/TAF
Description: 50/200/25 mg tablets administered orally once daily
Study: NCT04526951

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous injection of Tenecteplase and one dose of placebo tablet
Description: Drug: Tenecteplase Tenecteplase administered as an intravenous injection (0.25 mg/kg body weigh; maximum 25 mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: One tablet of Acetylsalicylic Acid and one dose of IV placebo
Description: 300 mg Acetylsalisylic acid
Study: NCT03739866

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B/F/TAF
Description: 50/200/25 mg tablets administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAF
Description: Tablets administered orally
Study: NCT04654624

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SDF
Description: Steps of SDF 38% application were carried out following the manufacturer's instructions. Eligible primary carious teeth were first dried and isolated using cotton rolls and gauze. Adjacent soft tissues were isolated using petrolleum gelly in order to prevent any irritation or staining from SDF that was directly placed into the carious lesion using a microbrush, allowed to absorb for 2 minutes, then dried with air. Parents were instructed that children should not eat for one hour after treatment. The second application was done after 6 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ART
Description: Steps of ART caries removal were carried out following the Frencken et al. criteria where the cavity opening was widened using the tip of a dental hatchet. The carious dentin was then removed using a spoon excavator starting at the enamel-dentin junction, unsupported enamel was removed using the hatchet, and finally the cavity was cleaned using a wet cotton pellet and dried. After complete removal of infected dentin, the cavity walls and floor were conditioned for 10 seconds, washed and dried with cotton pellets, then restored with chemically cured glass ionomer cement that was applied under finger pressure, then coated with petroleum jelly.
Study: NCT00918164

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04457845
Description: Single dose, 8 mg as oral tablet and solution formulation
Study: NCT04044599

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gynoflor
Description: VAGİNAL GYNOFLOR
Study: NCT00168818

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dabigatran etexilate
Description: daily dose 150 mg once daily, half a dose on the day of surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: enoxaparin
Description: 40 mg once daily
Study: NCT01422629

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasonic ablation device
Description: High Intensity focused ultrasound treatment
Study: NCT03462979

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Immunochromatographic lateral flow test
Description: The immunochromatographic lateral flow test (Gluten Detective) is an at-home test that detects gluten immunogenic peptides excreted in stool or urine. This test can detect gluten exposures which occurred either during the last 24 hours (urine) or within up to a 7 day window (stool). Minimum intake amounts of gluten for successful detection using these test are 50mg (stool) to 500mg (urine)
Study: NCT00625053

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic repair
Description: Complete adhesiolysis between viscera and abdominal wall, complete dissection of round ligament and subumbilical fatty tissue to expose the posterior fascia at least 5 cm further than the cranial and caudal limits of the fascial defect or the original incision. Overlap of minimum 5 cm is calculated and mesh inserted in the abdominal cavity through 12mm optical trocar. Fixation of a antiadhesive composite mesh with helicoidal pins with maximum 15mm interval, double crown technique. No pressure decrease maneuver is done during mesh fixation or at another time during the operation. No transparietal suture fixation. No fascial closure.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open midline incisional hernia repair
Description: * Underlay retromuscular repair: Medial border of the anterior fascia opened, posterior aspect of rectus muscle dissected to reach lateral border of rectus sheet, bilaterally. Peritoneum and posterior rectus fascia closed with absorbable running suture. Polyester or light-weight polypropylene mesh is cut to fit the reconstructed area, to have 3cm overlap on caudal and cranial defect limits. Mesh is fixed by absorbable sutures. Anterior fascia is closed with absorbable running suture. Components separation upon need.~* Intraperitoneal onlay repair: Mesh is inserted intraperitoneally and fixed by a complete running suture (optional fixation with helicoidal pins or stapler). Fascial defect is closed with interrupted or running absorbable suture. Components separation upon need.
Study: NCT02916667

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: dietary guidelines
Description: dietary guidelines will include chrono- nutrition diet plan

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: dietary guidelines
Description: dietary guidelines will include chrono- nutrition diet plan
Study: NCT03712943

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: Regorafenib orally 80 mg daily for 21 days (3 weeks on, 1 week off).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: Regorafenib orally 80 mg daily for 21 days (3 weeks on, 1 week off).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 240 mg administered intravenously every 2 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 240 mg administered intravenously every 2 weeks.
Study: NCT03452839

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meropenem
Description: Meropenem or injection vials to be re-constituted in a solution of NaCl 0.9%.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meropenem
Description: Meropenem or injection vials to be re-constituted in a solution of NaCl 0.9%.
Study: NCT04028193

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Calogen
Description: Polyunsaturated liquid fat supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Resource Energy
Description: Carbohydrate Supplement
Study: NCT03980574

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: R Drink
Description: R Drink is a dietary supplement drink containing filtered reverse osmosis water and 150 mg/L of both USP Grade calcium chloride and magnesium chloride, 10 mg/L Biotin (vitamin B7), 500 mg/L of Niacinamide (B3) and 550 mg/L of Choline.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: R Drink
Description: R Drink is a dietary supplement drink containing filtered reverse osmosis water and 150 mg/L of both USP Grade calcium chloride and magnesium chloride, 10 mg/L Biotin (vitamin B7), 500 mg/L of Niacinamide (B3) and 550 mg/L of Choline.
Study: NCT02218801

Intervention type: OTHER
Intervention: Evaluation of treatment for liver metastasis
Study: NCT02193334

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: KP-100IT

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04112186

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral group therapy #1
Description: Participants will participate in an 8-weeks of group therapy that uses psychological principles including mindfulness training, and could help decrease cravings for heroin and increase general well-being.
Study: NCT03739866

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAF
Description: Tablets administered orally
Study: NCT01218750

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Triple therapy for diffuse diabetic macular edema
Description: Three port pars plana vitrectomy is performed by one surgeon (JR). Induction of PVD is initiated by active suction with the vitrectomy probe over the ONH and continued peripherally. Peeling of the epimacular tissue and ILM is performed by grasping the flap of the ILM with an eckhardts forceps. Trypan Blue is used to stain the ILM. Peripheral laser endophotocoagulation is performed in cases of avascular areas based on FA, active neovascularization, peripheral retinoschisis or retinal breaks. All eyes have a 1,25 mg/0,05 ml bevacizumab injection into vitreous cavity and SF6 gas tamponade at the end of the procedure. Even of absence of cataract formation, a combined procedure is performed because of exactly peripheral vitreous shaving and prevention of cataract formation.
Study: NCT03900130

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Preload
Description: In the 2 x 2 factorial design we vary two factors:~1. caloric load of the preload such that it is either high calorie or low.~2. protein to carbohydrate ratio of the preload such that it is either high or low
Study: NCT03317158

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab (Cohort 1-3)
Description: Durvalumab 1120 mg intravenously Day 1 every 21 days x 8 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab (Cohort 1-3)
Description: Durvalumab 1120 mg intravenously Day 1 every 21 days x 8 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab (Cohort 1-3)
Description: Durvalumab 1120 mg intravenously Day 1 every 21 days x 8 cycles.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiotherapy (EBRT)
Description: EBRT 6 Gy x 3; Cycle 1 Day 1, 3, and 5

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bacillus Calmette-Guérin (BCG)
Description: Dose level 0 (starting dose) = Full-dose~Dose level-1 = 1/3rd-dose BCG. Dose level -1 is expected to be utilized during the phase II portion of the study due to the ongoing and persistent shortage of BCG in the US.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1000 mg intravesical weekly (+/- 2 days) x 6 doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1000 mg intravesical weekly (+/- 2 days) x 6 doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1000 mg intravesical weekly (+/- 2 days) x 6 doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 37.5 mg intravesical weekly (+/- 2 days) x 6 doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 37.5 mg intravesical weekly (+/- 2 days) x 6 doses.
Study: NCT00283803

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exisulind
Description: Oral antineoplastic agent that induces apoptosis in cancerous cells.
Study: NCT03317158

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 37.5 mg intravesical weekly (+/- 2 days) x 6 doses.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Tremelimumab 75 mg intravenously Day 1 (+/- 2 days) every 28 days x 4 cycles.
Study: NCT04112186

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral group therapy #2
Description: Participants will participate in an 8-weeks of group therapy that uses psychological principles (but not including mindfulness training) and could help decrease craving for heroin and increase general well-being.
Study: NCT03270878

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glasdegib Oral Tablet
Description: Subjects will receive a single 100 mg oral tablet of glasdegib under fasted conditions, either in study period 1 or 2, depending on randomization.
Study: NCT03317158

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab (Cohort 4/5)
Description: Durvalumab 1500 mg intravenously Day 1 (+/- 2 days) every 28 days x 6 cycles.
Study: NCT03270878

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glasdegib Oral Tablet
Description: Subjects will receive a single 100 mg oral tablet of glasdegib under fasted conditions, either in study period 1 or 2, depending on randomization.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glasdegib IV infusion
Description: Subjects will receive a 50 mg IV infusion of glasdegib over approximately 1.25 hours, in the fasted state, in either period 1 or 2 based on randomization.
Study: NCT03270878

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glasdegib IV infusion
Description: Subjects will receive a 50 mg IV infusion of glasdegib over approximately 1.25 hours, in the fasted state, in either period 1 or 2 based on randomization.
Study: NCT00387556

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: ondansetron (0.15 mg/kg/dose; maximum dose 4 mg)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ondansetron
Description: ondansetron (0.15 mg/kg/dose; maximum dose 4 mg)
Study: NCT03317158

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab (Cohort 4/5)
Description: Durvalumab 1500 mg intravenously Day 1 (+/- 2 days) every 28 days x 6 cycles.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: To be determined
Description: Other regimens to be determined
Study: NCT02421380

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperpolarized Pyruvate